OptiBiotix Health PLC Manufacturing Agreement with Tata Chemicals (7814P)
September 05 2017 - 1:00AM
UK Regulatory
TIDMOPTI
RNS Number : 7814P
OptiBiotix Health PLC
05 September 2017
OptiBiotix Health plc
("OptiBiotix" or "the Company")
Scale up and Manufacturing Agreement with Tata Chemicals
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing products to tackle obesity, high cholesterol and
diabetes, announces that it has entered into a scale up and
manufacturing agreement with Tata Chemicals ("TCL"). The Agreement
grants TCL a right to scale up and exclusively manufacture
galacto-oligosaccharide produced by OptiBiotix's LP-LDL(R) strain
(LPGOS) for the use in food and Over The counter (OTC) products,
subject to successful development of LPGOS at pilot level.
Tata Chemicals Limited ("TCL" or "Tata Chemicals"), is a global
science company active in industrial chemicals, food and nutrition,
and agriculture business, and is listed on the Indian stock
Exchange. It is part of the Tata Group of Companies which employs
over 660,000 employees with annual revenues in 2015/16 of $103.51
billion. Tata Chemicals Food and Nutrition business is a major
supplier of salts, spices, and nutritional solutions to the food,
beverage, nutraceutical and pharmaceutical industries within India
and increasingly across global markets.
The Agreement brings together TCL's expertise in the manufacture
of galacto-oligosaccharides with OptiBiotix's microbiome modulation
expertise to create products which selectively modify an
individual's microbiome to improve health. LPGOS has been shown in
gut models to:-
i. Increase the growth and biological activity of OptiBiotix's
cholesterol reducing strain (LP-LDL(R) ), leading to a threefold
increase in the strains cholesterol lowering ability
ii. Modify an individual's existing microbiome reducing cholesterol by up 22%
LPGOS is the first of a range of ingredients being developed by
OptiBiotix which can modify an individual's current microbiome to
improve health. OptiBiotix believes this creates opportunities to
use LPGOS in a wide range of food products to help reduce
cardiovascular risk factors and improve health. These ingredients
are heat resistant and stable during processing, which creates the
opportunity to incorporate low cost, safe, ingredients which
modulate specific elements of the microbiome in a wide range of
food products.
Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to
report this Agreement with Tata Chemicals which creates the
opportunity to scale up and manufacture galacto-oligosaccharide
produced by our LP-LDL(R) strain (LPGOS). Tata chemicals is one of
India's leading suppliers of food ingredients with many well known
and respected brands. We believe the combination of OptiBiotix's
ability to develop ingredients which can modify an individual's
microbiome, and Tata's research and manufacturing expertise,
international reputation, and global reach, places both companies
at the forefront of global microbiome research and product
development. I believe we are fast approaching the next stage in
the development of the microbiome in healthcare, where scientists
have the ability engineer components of the microbiome to prevent,
manage and treat many of today's chronic lifestyle diseases. This
agreement takes both companies further down the path of translating
the science of the microbiome field into products which will
improve the health and wellbeing of people around the world."
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook below
Cairn Financial Advisers LLP Tel: 020 7213 0880
Liam Murray
finnCap (Broker) Tel: 020 7220 0500
Adrian Hargrave / Scott Mathieson
Kate Bannatyne (Corporate Finance)
Tony Quirke (Corporate Broking)
Walbrook PR Ltd Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741 001
About OptiBiotix Health PLC - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which
modify the human microbiome - the collective genome of the microbes
in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial
strains, compounds and formulations, which modulate the human
microbiome and can be used as food ingredients and supplements or
active compounds for the prevention and management of human
diseases, examples of which include obesity, cholesterol and lipid
distribution, diabetes, and skin health.
OptiBiotix has established a pipeline of microbiome modulators
that can impact on lipid and cholesterol management, energy
harvest, appetite suppression, and skin health. The development
pipeline is fuelled by its proprietary OptiScreen(R) and
OptiBiotic(R) platform technologies designed to identify metabolic
pathways and compounds that impact on human physiology and bring
potential health benefits. These platforms are applicable across a
wider range of other human diseases.
About Tata Chemicals - www.tatachemicals.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGRLIMATMBAMBFR
(END) Dow Jones Newswires
September 05, 2017 02:00 ET (06:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2023 to Apr 2024